Cashu
Class Action Against uniQure N.V. Over Alleged Drug Approval Misrepresentation
3 days ago
Stocks
Health Care
qure
uniQure N.V.
NASDAQ: QURE
+0.55 (+3.73%)
15.28
USD
At close at Mar 19, 20:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
950.57M
Dividend Yield
0.00%
P/E Ratio
-4.78
EPS
-4.93
Revenue
27.12M
Avg. Volume
2.07M
About
What does QURE do?
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.